|
|
Epogen - News Articles
-
-
Amgen (AMGN, Fortune 500), for example, faces declining sales of its blockbuster anemia drug, Epogen. Gilead (GILD, Fortune 500) has had problems churning out new drugs outside of its trademark HIV franchise. Smaller biotechs, more likely to be acquisition targets, have fared better. "Investors have been slow to buy shares of the biggest biotechs because they'd rather ...
-
-
There were Franco's insulin and a bottle of Epogen, the medicine that had given him enough strength to live as long as he did. I hadn't ever wanted to touch them; I had wanted to keep them there, to remind me of him. Franco died two years ago, and this was not the first time I had mixed feelings about what to do with his things. One ...
-
-
In 2010, generic methotrexate made by Sandoz, Amgen's Epogen (epoetin alfa) and Baxter International's Hylenex (hyaluronidase recombinant) were among the medicine batches recalled because of the presence of lamellae in product vials. "Under certain conditions, glass vials can shed thin, flexible fragments … from the interior surface directly into the drug ...
-
-
In a note, Schoenebaum said the Centers for Medicare & Medicaid Services are expected to release a long-awaited draft rule on Amgen's anemia treatment Epogen next Wednesday, and the market is speculating that reimbursement for dialysis patients will remain unchanged. The NYSE Arca Biotechnology Index /quotes/comstock/10t!btk.x ( BTK 1,378 , +8.56 , +0.62% ) Â rose 1% ...
-
-
Its principal products include Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl ...
-
-
In a note sent to investors Goldman writes, "Implications are negative for Amgen (AMGN, Sell) as a decline in Epogen sales further pressures growth and creates greater pressure on the key pipeline driver, denosumab, to deliver, which we see as unlikely ...
-
-
Amgen Inc. is recalling certain lots of anemia drugs Epogen and Procrit, sold by Johnson & Johnson, because the vials may contain "extremely thin" glass ...
-
-
pay 20 percent of the dialysis base payment plus 20 percent of ESRD-related separately billable drugs, such as Amgen's Epogen used to treat anemia. However, patients currently do not pay co-insurance on separately billable lab tests. The new ESRD Prospective Payment System, released ...
-
-
Amgen has a monopoly with Epogen, used for patients on dialysis and other anemias. The margin is believed to exceed 85%. The pharmaceutical lobby is second to none. Hey, folks, I'm not against pharmaceutical medications. I take them, I prescribe them and I believe we ...
-
-
Pfizer is set on creating "bio-betters," Hospira is in the process of developing an Epogen biosimilar, and Cipla has inked a number of new deals which will help it build a discount biosimilars franchise. These developers won't have to conduct new trials of their drugs. But ...
-
-
Epogen is a medication that is frequently used to help increase the number of red blood cells in the body. It is used mainly in people with chronic kidney disease and for patients who are on dialysis. Epogenis a man made form of a protein of the hormone ...
-
-
global sales about $4.28 billion), and Epogen (for anaemia, global sales of about $2.49 billion) are slated to expire between 2012 and 2015. ...
-
-
The CEO also said he didn't know when the bottom would be reached for sales of Amgen's anemia drugs Epogen and Aranesp, which have come under scrutiny in ...
-
-
In addition to its five billion-dollar drugs (Epogen, Aranesp, Neupogen, Neulasta and Enbrel), recent drugs Prolia, Vectibix and Senspipar could all achieve ...
-
-
Unfavorable studies of its blockbuster anemia drugs Aranesp and Epogen, which account for 60 percent of the company's profit, and increased competition for its anti-inflammatory drug Enbrel, constitute only a portion of Amgen’s recent troubles. The company has also battled ...
-
-
He coordinated the design, construction and expansion of manufacturing facilities for Epogen(R) (epoetin alfa) and Neupogen(R) (filgrastim), ...
-
-
The news is a positive for the company, which is looking to replace revenues from two of its older drugs, Aranesp (darbepoetin alfa) and Epogen (epoetin alfa), which have been subject to label changes to reflect problems with this erythropoiesis-stimulating agents (ESAs) class of compounds. ...
-
-
The company's revenue and profits keep rising, along with new ways of delivering its core drugs Epogen and Aranesp. But big one ingredient has been missing — a rising share price. After a spectacular rise for nearly 15 years beginning in the mid-1980s, ...
-
-
Two kidney disease sufferers approached local media on Friday to express their concerns about the lack of Epogen – used to boost red blood cells following ...
-
-
This is no different than what Amgen did with Aranesp, which is a long-acting version of its best-selling drug Epogen. Both stimulate red blood cell production. Amgen wound up charging as much if not more for Aranesp to many customers. In other ...
Pages:
1
2
Next
|
|
